1. Home
  2. PBYI vs CYBN Comparison

PBYI vs CYBN Comparison

Compare PBYI & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$5.27

Market Cap

263.4M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$6.02

Market Cap

280.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBYI
CYBN
Founded
2010
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
263.4M
280.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PBYI
CYBN
Price
$5.27
$6.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$74.50
AVG Volume (30 Days)
637.1K
615.4K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
59.87
N/A
EPS
0.74
N/A
Revenue
$211,995,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$4.81
52 Week High
$6.12
$10.80

Technical Indicators

Market Signals
Indicator
PBYI
CYBN
Relative Strength Index (RSI) 55.90 49.09
Support Level $4.84 $5.50
Resistance Level $5.11 $6.23
Average True Range (ATR) 0.19 0.33
MACD 0.04 -0.00
Stochastic Oscillator 91.59 63.12

Price Performance

Historical Comparison
PBYI
CYBN

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: